Introduction
Thymic epithelial tumors account for 15-21.7% of mediastinal tumors and 47% of anterior mediastinal tumors (Chen et al., 2002; Engels and Pfeiffer, 2003). Until 2004, there was a wide range of pathological classifications for thymic tumors (Travis et al., 2004; Okumura et al., 2008). The World Health Organization (WHO) updated the pathological classification in 2004, and thymic tumors are now classified as one of 5 types of thymomas (types A, AB, B1, B2, and B3) or as thymic carcinoma (including neuroendocrine carcinoma) (Travis et al., 2004). Studies have suggested that this WHO classification reflects well the clinical and prognostic features of thymic tumors (Chen et al., 2002; Okumura et al., 2002; Kondo et al., 2004). There have been reports about the CT manifestations of thymic tumors with different WHO pathological classifications, but the number of cases in these reports was limited (Tomiyama et al., 2002; Han et al., 2003; Sadohara et al., 2006). To explore further the relationship between the CT manifestations and the WHO pathological classification, we conducted a retrospective analysis of 105 cases of thymic tumors.

Materials and Methods

Objective
This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Zhongnan Hospital of Wuhan University. Written informed consent was obtained from all participants.

Methods
Helical CT (PQ6000, PICKER, USA) and 16-slice CT (Somatom Sensation, Siemens, Germany) were used. The scan range was from the thoracic inlet to the diaphragmatic level. The slice thickness and interval were each 5 mm; 80-100 mL (300 mgI/mL) of the contrast agent Ultravist was injected at a rate of 3.0mL/s. Two senior physicians, both specialists in chest CT diagnosis, reviewed the imaging data, according to the recommendation of the Nomenclature Committee of the Fleischner Society (Hansell et al., 2008). They were told before the review

1Department of Radiology, 2Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China *For correspondence: yanjuanqu@126.com

Abstract

Objective: To explore the relationship between computed tomography (CT) manifestations of thymoma and its WHO pathological classification. Methods: One hundred and five histopathologically confirmed cases were collected for their pathological and CT characteristics and results were statistically compared between different pathological types of thymoma. Results: Tumor size, shape, necrosis or cystic change, capsule integrity, invasion to the adjacent tissue, lymphadenopathy, and the presence of pleural effusion were significantly different between different pathological types of thymomas (P <0.05). Type B2, B3 tumors and thymic carcinomas were greater in size than other types. More than 50% of type B3 tumors and thymic carcinomas had a tumor size greater than 10 cm. The shape of types A, AB, and B1 tumors were mostly round or oval, whereas 75% of type B3 tumors and 85% of thymic carcinomas were irregular in shape. Necrosis or cystic change occurred in 67% of type B3 thymomas and 57% of thymic carcinomas, respectively. The respective figures for capsule destruction were 83% and 100%. Increases in the degree of malignancy were associated with increases in the incidence of surrounding tissue invasion: 33%, 75%, and 81% in type B2, type B3, and thymic carcinomas, respectively. Pleural effusion occurred in 48% of thymic carcinomas, while calcification was observed mostly in type B thymomas. Conclusions: Different pathological types of thymic epithelial tumors have different CT manifestations. Distinctive CT features of thymomas may reflect their pathological types.

Keywords: CT - thymus - thymic epithelial tumors - thymic carcinomas - pathology

Asian Pacific J Cancer Prev, 13 (11), 5581-5585

Research Article

Relationship Between Computed Tomography Manifestations of Thymic Epithelial Tumors and the WHO Pathological Classification

Guo-Bing Liu1, Yan-Juan Qu1*, Mei-Yan Liao1, Hui-Juan Hu1, Gui-Fang Yang2, Su-Jun Zhou1


DOI:http://dx.doi.org/10.7314/APJCP.2012.13.11.5581
that the patients had thymic epithelial tumors, but they were blind to the specific pathological classification. They reached a consensus through discussion. Diameters were measured in cross-sectional images. The tumor size was the long-axis diameter. Based on this, tumors were divided into three groups: <5.0 cm, 5.0 ~ 10.0 cm, and >10.0 cm. The tumor shape was evaluated based on the ratio of the long axis diameter to the short axis diameter. The tumor shape was designated round, oval, or irregular if the ratio was <1.5, 1.5-3.0, or ≥3.0, respectively (Tomiyama et al., 2002). Capsule destruction was noted if more than 1/3 of the capsule on the tumor edge was damaged (Tomiyama et al., 2001). The presence of necrosis or cystic change was indicated by lack of enhancement in the intratumor low-density areas. Lymphadenopathy was indicated by a short-axis diameter of the lymph node ≥10 mm. Adjacent tissue invasion included invasion of the blood vessels, pleura, pericardium, and lung tissue. Disappearance of the fat plane between the tumor and vessels, accompanied by focal deformation of blood vessels, tumor thrombus, and vascular obstruction, indicated vascular invasion (Marom, 2010; Marom et al., 2011). Pericardial invasion was noted if the tumor adhered strongly to the pericardium and the pericardium appeared as thickened. Pleural thickening indicated pleural invasion. Pulmonary infiltration was defined as adhesions between the tumor and adjacent lung tissues, poor inflation of the lung under compression, or small patchy consolidation of the adjacent lung tissue (Yang et al., 1997).

Table 1. Main Clinical Data and Pathological Classifications

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>A</th>
<th>AB</th>
<th>B1</th>
<th>B2</th>
<th>B3</th>
<th>Thymic carcinoma</th>
<th>χ²</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>6</td>
<td>10</td>
<td>10</td>
<td>8</td>
<td>6</td>
<td>12</td>
<td>1.0589</td>
<td>0.9577</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>13</td>
<td>12</td>
<td>7</td>
<td>6</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 years</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>9.1758</td>
<td>0.5155</td>
</tr>
<tr>
<td>40-60 years</td>
<td>6</td>
<td>14</td>
<td>13</td>
<td>9</td>
<td>6</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60 years</td>
<td>3</td>
<td>7</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Relationship Between CT Manifestations and Pathological Classifications

<table>
<thead>
<tr>
<th>CT manifestations</th>
<th>A</th>
<th>AB</th>
<th>B1</th>
<th>B2</th>
<th>B3</th>
<th>Thymic carcinoma</th>
<th>χ²</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>7(58%)</td>
<td>12(52%)</td>
<td>10(45%)</td>
<td>7(46%)</td>
<td>2(17%)</td>
<td>2(10%)</td>
<td>23.6746</td>
<td>0.0085</td>
</tr>
<tr>
<td>5~10</td>
<td>4(33%)</td>
<td>8(35%)</td>
<td>9(41%)</td>
<td>4(27%)</td>
<td>3(25%)</td>
<td>8(38%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;10</td>
<td>1(9%)</td>
<td>3(13%)</td>
<td>3(14%)</td>
<td>4(27%)</td>
<td>7(58%)</td>
<td>11(52%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shape</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Round</td>
<td>7(58%)</td>
<td>8(35%)</td>
<td>5(23%)</td>
<td>3(20%)</td>
<td>1(8%)</td>
<td>1(5%)</td>
<td>30.3933</td>
<td>0.0007</td>
</tr>
<tr>
<td>Oval</td>
<td>4(33%)</td>
<td>9(39%)</td>
<td>7(32%)</td>
<td>5(34%)</td>
<td>2(17%)</td>
<td>2(10%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irregular</td>
<td>1(9%)</td>
<td>6(26%)</td>
<td>10(45%)</td>
<td>7(46%)</td>
<td>9(75%)</td>
<td>18(85%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcification</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2(17%)</td>
<td>3(13%)</td>
<td>6(27%)</td>
<td>5(33%)</td>
<td>3(25%)</td>
<td>4(19%)</td>
<td>2.9315</td>
<td>0.7105</td>
</tr>
<tr>
<td>No</td>
<td>10(83%)</td>
<td>20(87%)</td>
<td>16(73%)</td>
<td>10(67%)</td>
<td>9(75%)</td>
<td>17(81%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Necrosis or cystic change</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>7(58%)</td>
<td>12(52%)</td>
<td>10(45%)</td>
<td>7(46%)</td>
<td>2(17%)</td>
<td>2(10%)</td>
<td>23.6746</td>
<td>0.0085</td>
</tr>
<tr>
<td>No</td>
<td>10(83%)</td>
<td>18(76%)</td>
<td>10(41%)</td>
<td>7(46%)</td>
<td>6(36%)</td>
<td>9(44%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsular destruction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1(8%)</td>
<td>3(13%)</td>
<td>5(23%)</td>
<td>7(47%)</td>
<td>10(83%)</td>
<td>21(100%)</td>
<td>53.2763</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>11(92%)</td>
<td>20(87%)</td>
<td>17(77%)</td>
<td>8(53%)</td>
<td>2(17%)</td>
<td>0(0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasion of adjacent tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1(8%)</td>
<td>2(9%)</td>
<td>2(9%)</td>
<td>5(33%)</td>
<td>9(75%)</td>
<td>17(81%)</td>
<td>48.9044</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>12(100%)</td>
<td>21(91%)</td>
<td>20(91%)</td>
<td>10(67%)</td>
<td>3(25%)</td>
<td>4(19%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1(8%)</td>
<td>2(9%)</td>
<td>4(18%)</td>
<td>6(40%)</td>
<td>7(58%)</td>
<td>15(71%)</td>
<td>29.3196</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No</td>
<td>11(92%)</td>
<td>21(91%)</td>
<td>18(82%)</td>
<td>9(60%)</td>
<td>5(42%)</td>
<td>6(29%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleural effusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0(0%)</td>
<td>1(4%)</td>
<td>2(9%)</td>
<td>3(20%)</td>
<td>6(50%)</td>
<td>10(48%)</td>
<td>24.0164</td>
<td>0.0002</td>
</tr>
<tr>
<td>No</td>
<td>12(100%)</td>
<td>22(96%)</td>
<td>20(91%)</td>
<td>12(80%)</td>
<td>6(50%)</td>
<td>11(52%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Statistical analysis

SPSS11.0 software was used for statistical analysis. The between-group comparisons of gender, age, and CT manifestations – including tumor size, tumor shape, calcification, necrosis or cystic change, capsular integrity, surrounding organ invasion, lymphadenopathy, and pleural effusion – were compared using the χ² test or Fisher exact probability test. P <0.05 indicated a statistically significant difference.

Results

General data

Of the 105 cases in this study, 52 were male and 53 were female. Patient ages ranged from 18 to 75 years and the average age was 47.98 ± 12.54 years. There was no
significant difference in size between types A, AB, and B1, ± 4.98, and 11.00 ± 3.74 cm, respectively. There was no
6.33 ± 3.41, 6.00 ± 3.30, 6.38 ± 3.79, 7.32 ± 4.60, 12.40
B1, B2, and B3 thymic tumors and thymic carcinoma were
an average of 8.65 ± 3.86 cm. The sizes of types A, AB,
(2). The tumor size ranged from 2.0 to 18.5 cm with
between different pathological types of thymic tumors
invasion of the adjacent tissue, lymphadenopathy, and the
tumor shape, necrosis or cystic change, capsule integrity,
resection while 40 received partial resection. Tumor size,
the CT examination. Sixty-five cases underwent complete
All 105 cases underwent plain CT scan and enhanced
classifications
Before 2004, the pathological classification of thymic epithelial tumors was confusing and considerably different
from that of today (Rosai and Sobin, 1999). The current
WHO classification is as follows (Travis et al., 2004;
Okumura et al., 2008): type A tumor, composed of a
homogeneous population of neoplastic epithelial cells
having spindle-like and oval shapes, lacking nuclear
atypia, and accompanied by few or no non-neoplastic
lymphocytes; type AB tumor, foci with the features of type
A thymoma are admixed with foci rich in lymphocytes,
but the sizes of types B2 and B3 and thymic carcinoma
were significantly different from those of other types
of thymic tumors. More than half of the type B3 thymic
tumors (58%) and thymic carcinomas (52%) had a tumor
size greater than 10 cm. The percentage of tumors with
an irregular shape increased in various types of thymic
tumors, from low to high in the following sequence: types
A, AB, B1, B2, B3, and thymic carcinoma. The shapes of
types A, AB, and B1 thymic tumors were mostly round or
oval; 75% of type B3 thymic tumors and 85% of thymic
carcinomas were irregular in shape. Necrosis or cystic
change occurred in 67% of type B3 thymomas and 57%
of thymic carcinomas, respectively. Capsule destruction
occurred in 47% of type B2 thymomas, 83% of type B3
thymomas and 100% of thymic carcinomas. The incidence
of surrounding tissue invasion increased with increases
in the degree of malignancy. The incidence of surrounding
tissue invasion was 33%, 75%, and 81% in type B2,
type B3, and thymic carcinomas, respectively. Pleural
effusion occurred in 50% of type B3 thymomas and 48%
of thymic carcinomas. There was no significant difference
in calcification between the different pathological
classifications. Calcification occurred in 29% of type B
thymomas.

Discussion

Before 2004, the pathological classification of thymic epithelial tumors was confusing and considerably different
from that of today (Rosai and Sobin, 1999). The current
WHO classification is as follows (Travis et al., 2004;
Okumura et al., 2008): type A tumor, composed of a
homogeneous population of neoplastic epithelial cells
having spindle-like and oval shapes, lacking nuclear
atypia, and accompanied by few or no non-neoplastic
lymphocytes; type AB tumor, foci with the features of type
A thymoma are admixed with foci rich in lymphocytes,
with sharp or indistinct segregation of the two patterns;
type B1 tumor, resembles the normal functional thymus
in that it combines large expanses with an appearance
practically indistinguishable from that of normal thymic
cortex with areas resembling thymic medulla; type B2
tumor, the neoplastic epithelial component appears as
scattered plump cells with vesicular nuclei and distinct
nucleoli among a predominant population of lymphocytes
(perivascular spaces are common); type B3 tumor,
predominantly composed of epithelial cells with a round or polygonal shape and exhibiting mild atypia admixed with a minor component of lymphocytes (foci of squamous metaplasia and perivascular spaces are common) (Figure 1A); thymic carcinoma (Figure 1B). The classification of types A, AB, B1, and B2 tumors does not specify which tumor types are encapsulated thymomas and invasive thymomas, but the classification of type B3 corresponds to atypical thymoma and thymic carcinoma. The WHO classification reflects the clinical and functional characteristics of thymic epithelial tumors, and thus is helpful for clinical assessment and treatment (Chen et al., 2002; Okumura et al., 2002; Kondo et al., 2004). Okumura et al. reported that types B2 and B3 thymomas had a higher recurrence rate and poorer prognosis than types A, AB, and B1 thymomas (Okumura et al., 2002); In stage I and II thymomas, the WHO subtype is an independent influencing factor (Chen et al., 2002).

Thymic tumors often occur in patients over the age of 40, with a similar incidence in men and women. In this study, representation of men and women was similar, while the average age was 48. Thymic tumors are rarely found in children or adolescents. The youngest patient in this study was 18 years old. There was no significant difference in age or gender between the different pathological classification groups, consistent with reports in the literature (Sadohara et al., 2006). CT data is an important basis for the selection of treatment for thymic tumors. In the literature, thymic epithelial tumors are divided into low-risk thymomas (types A, AB, and B1), high-risk thymomas (types B2 and B3), and thymic carcinomas. Tumor invasiveness increases gradually. CT signs reflect tumor characteristics well (Sadohara et al., 2006; Priola et al., 2010). In this study, tumor size, tumor shape, necrosis or cystic change, capsule integrity, invasion of the adjacent tissue, lymphadenopathy and the presence of pleural effusion were significantly different between the different pathological types of thymic tumors. The malignant characteristics of type B2 and B3 thymomas and thymic carcinomas were obvious, consistent with previous reports (Tomiyama et al., 2002; Han et al., 2003; Sadohara et al., 2006).

The size of thymic tumors is associated with classification. The greater the tumor mass, the higher the probability the tumor is malignant (Yanagawa and Tomiyama, 2011). In particular, thymomas >10 cm are often type B or thymic carcinoma (Yanagawa and Tomiyama, 2011). In this study, 7 (7/12, 58%) cases of type B3 and 11 (11/21, 52%) cases of thymic carcinoma were greater than 10 cm in size. Type A and type AB thymic tumors are often round or oval with a clear, smooth edge and a uniform density (Figure 2A); Type B and thymic carcinomas are often irregular in shape or lobulated, though; the lobulation rate is greater than 60% (Tomiyama et al., 2002). Chen et al. reported a lobulation rate of 89% (Okumura et al., 2004). In this study, 91% and 74% of type A and type AB thymomas, respectively, were round or oval, while 46%, 75%, and 85% of type B2 thymomas, type B3 thymomas, and thymic carcinomas, respectively, were irregularly shaped, supporting the aforementioned point of view.

Sadohara et al. (2006) reported that necrosis or cystic change occurred in 67% of thymic carcinomas. In this study, necrosis or cystic change occurred in 67% and 57% of type B3 thymomas and thymic carcinomas, respectively, consistent with the previous study. Tomiyama et al. reported that calcification is most common in type B thymomas (Tomiyama et al., 2002). In this study, the calcification rate in type B thymomas was 25-33%, higher than that of the other types of thymic tumors. Our results are consistent with Tomiyama et al.’s results.

It is reported that the capsule was intact in the majority of type A and type AB thymomas, but capsular infiltration might occur in some of them (Figure 2B) (Chen et al., 2002). Capsule destruction is an important CT manifestation of type B thymoma and thymic carcinoma. Surrounding organ invasion (which mainly refers to the invasion of the pleura, pericardium, and great blood vessels) and distant metastasis occur only in type B and thymic carcinoma (Figure 2C, D) (Marom, 2010; Marom et al., 2011). Relying on the fuzzy capsule in CT images as the determining criteria for capsular invasion would lead to errors. Research suggests that MRI is superior to CT in displaying tumor capsule, septum, and intratumoral hemorrhage (Sadohara et al., 2006). In this study, capsule destruction occurred in one case of type A thymoma. The incidence of capsule destruction was 83% in type B3 thymomas and 100% in thymic carcinomas. In types B1, B2, and B3 thymomas as well as in thymic carcinomas, the incidence of capsule destruction increases with increased atypia. The axial CT images and combined multi-planar reconstruction may be used to accurately identify thymic tumor invasion of the adjacent blood vessels, pericardium, and lung tissue (Figure 3A, B). In this study, adjacent tissue invasion occurred in 75% and 81% of type B3 thymomas and thymic carcinomas, respectively, similar to the percentage reported in the literature (Jung et al., 2001; Sadohara et al., 2006). The prognosis is poor if vascular invasion occurs.

Using CT to determine the clinical stage of thymic tumors may help in the selection of treatment protocol as well as in determining the prognosis (Nakagawa et al., 2003; Yanagawa and Tomiyama, 2011). If the malignant thymoma has a cast-like relationship with great blood vessels, the tumor is unresectable (Maher and Shepard, 2005; Marom, 2010; Yanagawa and Tomiyama, 2011). Tian et al. (2003) reported that CT could reach a staging accuracy of 87.5%, a specificity of 90%, and a sensitivity of 83.3%. Imaging assessment plays an important role in the clinical diagnosis and treatment of thymic tumors (Yanagawa and Tomiyama, 2011). Complete resection of the tumor is the best treatment method and the most important prognostic factor (Kondo and Monden, 2003; Strobel et al., 2004). Types A, AB, and B1 thymomas require no further treatment after complete resection. Stage I and II types B2 and B3 thymomas require adjuvant radiotherapy after complete resection. The recurrence rate is 34% in incompletely resected types B2 and B3 thymomas, and in stage III or higher thymomas after adjuvant radiotherapy; it is 78% in patients who do not receive radiotherapy (Strobel et al., 2004). If a tumor has a smooth margin, homogeneous density, and...
no obvious necrosis or cystic change, it often can be resected completely. If a tumor is lobulated or irregular in shape and has heterogeneous enhancement, it is often a highly invasive thymoma or thymic carcinoma. MRI is recommended for further assessment as MRI facilitates the assessment of local invasion (Tomiyama et al., 2002).

Acknowledgements

The author(s) declare that they have no competing interests. This study was supported by The Natural Science Foundation of Hubei Province. Project Number: 2012FFB04422.

References